MediciNova: Differentiated NAFLD/MASH Profile and Complementary APOC3 Positioning Support Unchanged $6 Target and Buy Rating

Medicinova, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from Maxim Group maintained a Buy rating on the stock and has a $6.00 price target.

Claim 55% Off TipRanks

• Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
• Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Jason McCarthy has given his Buy rating due to a combination of factors tied to MediciNova’s differentiated profile in metabolic disease. He notes that recent Phase 3 success by Arrowhead in severe hypertriglyceridemia validates APOC3 biology and the commercial potential of triglyceride-lowering therapies, while simultaneously underscoring that triglyceride reduction alone does not address liver fat or liver enzyme abnormalities.

In this context, MN-001’s oral, multi-mechanistic approach, which has shown the ability to lower both triglycerides and liver fat and to raise HDL in a diabetic NAFLD population, positions it for a potentially broader role in NAFLD/MASH with coexisting hypertriglyceridemia and type 2 diabetes. McCarthy also highlights the upcoming Phase 2 readout in this mixed population as a key catalyst and argues that MN-001 is complementary rather than directly competitive to APOC3 agents, supporting his unchanged $6 price target and Buy recommendation.

McCarthy covers the Healthcare sector, focusing on stocks such as Medicinova, Inmune Bio, and AIM ImmunoTech. According to TipRanks, McCarthy has an average return of -13.0% and a 30.06% success rate on recommended stocks.

In another report released on July 15, H.C. Wainwright also maintained a Buy rating on the stock with a $10.00 price target.